S-4.2, r. 23 - Regulation respecting the information that institutions must provide to the Minister of Health and Social Services

Schedule Disposition versions

2022-04-14

Schedule V.1

(s. 5.1.1)

1. The institution referred to in section 5.1.1 must provide the following information in respect of any user suffering from cancer:

(1)  concerning the user:

(a)  the name of the user’s mother;

(b)  the name of the user’s father;

(c)  if the user died:

i.  the date of death;

ii.  the province, territory or country where the user died;

iii.  the number, on the institution’s permit, of the facility where the user died or, failing that, the number of the institution that maintains the facility, where applicable;

(2)  concerning a user diagnosed with cancer:

(a)  the date of the diagnosis;

(b)  the number, on the institution’s permit, of the facility where the diagnosis is established or, failing that, the number of the institution that maintains the facility;

(c)  the name and code of the municipality where the user’s residence is located at the time of the diagnosis;

(d)  the methods used to establish and confirm the diagnosis;

(e)  the class assigned to a cancer case, according to the place of diagnosis and treatment;

(f)  the behaviour of the tumor according to the International Classification of Diseases for Oncology (ICD-O);

(g)  the tumor grade according to the clinical evaluation and the pathological evaluation, and after the post neoadjuvant treatment, where applicable, according to the classification of the North American Association of Central Cancer Registries or, if the cancer was diagnosed before 2018, the grade of the tumor according to the ICD-O;

(h)  the histology of the tumor according to the ICD-O;

(i)  the presence or absence of lymphovascular invasion;

(j)  the tumor laterality;

(k)  the topography of the primary site of the tumor according to the ICD-O;

(3)  concerning a user diagnosed with colorectal, lung, prostate or breast cancer:

(a)  according to the clinical evaluation and the pathological evaluation of the tumor carried out before the first line of treatment, where applicable, according to the classification of the Cancer Staging Manual of the American Joint Committee on Cancer:

i.  the evaluation of the size or extension of the tumor;

ii.  the observation of the presence or absence of regional lymph node metastases and the extension of their effect;

iii.  the observation of the presence or absence of distant metastases;

iv.   the TNM stage (Tumor Node Metastasis) of the tumor;

v.  the specifications made by adding a suffix to the evaluation of the size or extension of the tumor and to the observation of the presence or absence of regional lymph node metastases and the extension of their effect or, if the cancer was diagnosed before 2018, the specifications made by adding a prefix or a suffix to the TNM stage;

(b)  regarding the evaluation carried out after the post neoadjuvant treatment, where applicable:

i.  the evaluation of the size or extension of the tumor;

ii.  the observation of the presence or absence of regional lymph node metastases and the extension of their effect;

iii.  the observation of the presence or absence of distant metastases;

iv.  the TNM stage of the tumor;

v.  the specifications made by adding a suffix to the evaluation of the size or extension of the tumor and to the observation of the presence or absence of regional lymph node metastases and the extension of their effect;

(c)  an indication that the cancer is treated, not treated or under active supervision;

(4)  concerning a user diagnosed with prostate cancer, the value of the prostate specific antigen test;

(5)  concerning a user diagnosed with breast cancer:

(a)  summaries of test results of estrogen receptors, progesterone receptors and the human epidermal growth factor receptor 2 of the tumor;

(b)  the result of the Oncotype DX Breast Recurrence Score test;

(6)  concerning the treatment of colorectal, lung, prostate or breast cancer:

(a)  the date on which the first line of treatment begins;

(b)  the date of the first surgical procedure, where applicable;

(c)  regarding the most important surgical resection performed on the primary site of the cancer, where applicable:

i.  the date of the intervention;

ii.  the number, on the institution’s permit, of the facility where the intervention was performed or, failing that, the number of the institution that maintains the facility;

iii.  the type of surgical procedure performed;

iv.  the state of surgical margins after the intervention;

(d)  regarding administered radiotherapy treatment, where applicable:

i.  the date on which the treatment begins;

ii.  the number, on the institution’s permit, of the facility where the treatment was administered or, failing that, the number of the institution that maintains the facility;

iii.  the anatomic target of the treatment;

(e)  regarding administered chemotherapy, hormonal therapy or immunotherapy treatment, where applicable :

i.  the date on which the treatment begins;

ii.  the number, on the institution’s permit, of the facility where the treatment was administered or, failing that, the number of the institution that maintains the facility;

(f)  regarding administered palliative treatment, where applicable:

i.  the type of treatment administered;

ii.  the number, on the institution’s permit, of the facility where the treatment was administered or, failing that, the number of the institution that maintains the facility.

2. An institution referred to in section 5.1.1 of the Regulation must provide the following information in respect of any user for whom a request for a radiation oncology consultation is made or to whom radiation oncology treatment is administered:

(1)  the date of receipt of the request for consultation;

(2)  the clinical priority code assigned to the user’s cancer;

(3)  the date of the first consultation;

(4)  an indication that the administration of radiotherapy treatment was deemed appropriate following the consultation;

(5)  the date as of which the user is deemed ready to receive a first radiotherapy treatment;

(6)  regarding the radiotherapy treatment administered or determined following the consultation:

(a)  the date on which it is administered for the first time;

(b)  its anatomic target;

(c)  an indication of whether it is teletherapy treatment or brachytherapy treatment;

(d)  in the case of teletherapy treatment, the planning technique used in accordance with the financial management manual published by the Minister under section 477 of the Act respecting health services and social services (chapter S-4.2);

(e)  the name of the treatment plan;

(f)  an indication of whether the treatment is curative or palliative;

(g)  the number of treatment fractions scheduled;

(7)  for each period of the user’s unavailability:

(a)  the dates on which the user’s unavailability begins and ends;

(b)  an indication of whether the unavailability is due to personal or medical reasons;

(8)  the explanations of the institution regarding any delays incurred and any period of unavailability reported.

3. An institution referred to in section 5.1.1 of the Regulation must provide the following information in respect of any user for whom a request for an oncology consultation or a hematology consultation is made or to whom oncology or hematology treatment is administered:

(1)  the date of receipt of the request for consultation;

(2)  the priority code assigned to the request;

(3)  the date of the first consultation;

(4)  the tumour site of the cancer concerned by the treatment, where applicable;

(5)  if the request for consultation concerns a user whose cancer diagnosis has not been confirmed, an indication that the user is awaiting a diagnosis;

(6)  an indication that, following the consultation, it was determined that the user does not have neoplasia, where applicable;

(7)  an indication that the administration of systemic treatment (chemotherapy, targeted therapy or immunotherapy) was deemed appropriate following the consultation or that the treatment plan has not yet been determined;

(8)  regarding the systemic treatment administered or determined following the consultation:

(a)  the date on which it is administered for the first time;

(b)  an indication of whether it is administered orally or intravenously;

(c)  in the case of intravenous systemic treatment:

i.  an indication that the treatment is administered in an institution other than the institution where the consultation was carried out, where applicable;

ii.  an indication that the treatment is administered simultaneously with radiotherapy, where applicable;

(9)  if the administration of systemic treatment was not deemed appropriate following the consultation, an indication of whether another treatment will be administered or that only active follow-up will be maintained;

(10)  for each period of the user’s unavailability:

(a)  the dates on which the user’s unavailability begins and ends;

(b)  an indication of whether the unavailability is due to personal or medical reasons;

(11)  the explanations of the institution regarding any delays incurred and any period of unavailability reported.

4. Every transmission of the information required under sections 2 and 3 must be accompanied by the following:

(1)  the year, financial period and week number concerned;

(2)  the name and permit number of the institution concerned;

(3)  the name and number, on the institution’s permit, of the facility concerned.

O.C. 759-2019, s. 5; O.C. 317-2022, s. 5.

2019-08-01

Schedule V.1

(s. 5.1.1)

1. The institution referred to in section 5.1.1 must provide the following information:

(1)  concerning the user:

(a)  the name of the user’s mother;

(b)  the name of the user’s father;

(c)  if the user died:

i.  the date of death;

ii.  the province, territory or country where the user died;

iii.  the number, on the institution’s permit, of the facility where the user died or, failing that, the number of the institution that maintains the facility, where applicable;

(2)  concerning a user diagnosed with cancer:

(a)  the date of the diagnosis;

(b)  the number, on the institution’s permit, of the facility where the diagnosis is established or, failing that, the number of the institution that maintains the facility;

(c)  the name and code of the municipality where the user’s residence is located at the time of the diagnosis;

(d)  the methods used to establish and confirm the diagnosis;

(e)  the class assigned to a cancer case, according to the place of diagnosis and treatment;

(f)  the behaviour of the tumor according to the International Classification of Diseases for Oncology (ICD-O);

(g)  the tumor grade according to the clinical evaluation and the pathological evaluation, and after the post neoadjuvant treatment, where applicable, according to the classification of the North American Association of Central Cancer Registries or, if the cancer was diagnosed before 2018, the grade of the tumor according to the ICD-O;

(h)  the histology of the tumor according to the ICD-O;

(i)  the presence or absence of lymphovascular invasion;

(j)  the tumor laterality;

(k)  the topography of the primary site of the tumor according to the ICD-O;

(3)  concerning a user diagnosed with colorectal, lung, prostate or breast cancer:

(a)  according to the clinical evaluation and the pathological evaluation of the tumor carried out before the first line of treatment, where applicable, according to the classification of the Cancer Staging Manual of the American Joint Committee on Cancer:

i.  the evaluation of the size or extension of the tumor;

ii.  the observation of the presence or absence of regional lymph node metastases and the extension of their effect;

iii.  the observation of the presence or absence of distant metastases;

iv.   the TNM stage (Tumor Node Metastasis) of the tumor;

v.  the specifications made by adding a suffix to the evaluation of the size or extension of the tumor and to the observation of the presence or absence of regional lymph node metastases and the extension of their effect or, if the cancer was diagnosed before 2018, the specifications made by adding a prefix or a suffix to the TNM stage;

(b)  regarding the evaluation carried out after the post neoadjuvant treatment, where applicable:

i.  the evaluation of the size or extension of the tumor;

ii.  the observation of the presence or absence of regional lymph node metastases and the extension of their effect;

iii.  the observation of the presence or absence of distant metastases;

iv.  the TNM stage of the tumor;

v.  the specifications made by adding a suffix to the evaluation of the size or extension of the tumor and to the observation of the presence or absence of regional lymph node metastases and the extension of their effect;

(c)  an indication that the cancer is treated, not treated or under active supervision;

(4)  concerning a user diagnosed with prostate cancer, the value of the prostate specific antigen test;

(5)  concerning a user diagnosed with breast cancer:

(a)  summaries of test results of estrogen receptors, progesterone receptors and the human epidermal growth factor receptor 2 of the tumor;

(b)  the result of the Oncotype DX Breast Recurrence Score test;

(6)  concerning the treatment of colorectal, lung, prostate or breast cancer:

(a)  the date on which the first line of treatment begins;

(b)  the date of the first surgical procedure, where applicable;

(c)  regarding the most important surgical resection performed on the primary site of the cancer, where applicable:

i.  the date of the intervention;

ii.  the number, on the institution’s permit, of the facility where the intervention was performed or, failing that, the number of the institution that maintains the facility;

iii.  the type of surgical procedure performed;

iv.  the state of surgical margins after the intervention;

(d)  regarding administered radiotherapy treatment, where applicable:

i.  the date on which the treatment begins;

ii.  the number, on the institution’s permit, of the facility where the treatment was administered or, failing that, the number of the institution that maintains the facility;

iii.  the anatomic target of the treatment;

(e)  regarding administered chemotherapy, hormonal therapy or immunotherapy treatment, where applicable :

i.  the date on which the treatment begins;

ii.  the number, on the institution’s permit, of the facility where the treatment was administered or, failing that, the number of the institution that maintains the facility;

(f)  regarding administered palliative treatment, where applicable:

i.  the type of treatment administered;

ii.  the number, on the institution’s permit, of the facility where the treatment was administered or, failing that, the number of the institution that maintains the facility.

O.C. 759-2019, s. 5.